Fulzos 250mg Injection contains Fulvestrant, a selective estrogen receptor degrader used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Fulvestrant works by binding to estrogen receptors and accelerating their degradation, thereby inhibiting estrogen-driven tumor growth. This injection is administered intramuscularly, typically once a month, allowing for sustained suppression of estrogen receptor activity. Fulzos 250mg is indicated for patients who have progressed on prior endocrine therapy or as a first-line treatment in certain cases. The medication is generally well-tolerated, though some patients may experience side effects such as injection site pain, nausea, fatigue, hot flashes, or mild gastrointestinal disturbances. It is essential to monitor liver function during treatment, as Fulvestrant can occasionally cause elevated liver enzymes. Fulzos 250mg Injection should be used under the supervision of an oncologist, with careful consideration of the patient’s overall health status and concurrent medications to avoid potential interactions. By effectively reducing estrogen receptor levels, Fulzos 250mg Injection offers a targeted therapeutic option that can improve disease control and quality of life in patients with advanced breast cancer.